<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2e524986-7903-416f-b2b8-d27295103e75"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use <content styleCode="bold">Doxazosin</content> safely and effectively.  See full prescribing information for <content styleCode="bold">Doxazosin</content>.<br/> <br/>
      <content styleCode="bold">Doxazosin tablets, for oral use</content>
      <br/>Initial U.S. Approval: 1990</title>
   <effectiveTime value="20240311"/>
   <setId root="2e524986-7903-416f-b2b8-d27295103e75"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="059295980" root="1.3.6.1.4.1.519.1"/>
            <name>Mylan Pharmaceuticals Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="059295980" root="1.3.6.1.4.1.519.1"/>
                  <name>Mylan Pharmaceuticals Inc.</name>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="e91981a5-e204-451c-b0a6-3ec1d37c5f98"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20240311"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="59762-1388" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Doxazosin mesylate</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>doxazosin mesylate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="1"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="86P6PQK0MU" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DOXAZOSIN MESYLATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="NW1291F1W8" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DOXAZOSIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="J2B2A4N98G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE, UNSPECIFIED FORM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="59762-1388-7" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250509"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA019668" root="2.16.840.1.113883.3.150"/>
                           <code code="C73605" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA authorized generic"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250509"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">CN1;VLE</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="59762-1389" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Doxazosin mesylate</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>doxazosin mesylate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="2"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="86P6PQK0MU" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DOXAZOSIN MESYLATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="NW1291F1W8" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DOXAZOSIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="J2B2A4N98G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE, UNSPECIFIED FORM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="59762-1389-7" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20300101"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA019668" root="2.16.840.1.113883.3.150"/>
                           <code code="C73605" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA authorized generic"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250509"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>oblong</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">CN;2;VLE</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="59762-1390" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Doxazosin mesylate</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>doxazosin mesylate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="4"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="86P6PQK0MU" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DOXAZOSIN MESYLATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="NW1291F1W8" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DOXAZOSIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="J2B2A4N98G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE, UNSPECIFIED FORM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="59762-1390-7" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20300101"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA019668" root="2.16.840.1.113883.3.150"/>
                           <code code="C73605" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA authorized generic"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250509"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="12" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48338" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="DIAMOND" xsi:type="CE">
                              <originalText>rhombus</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">CN;4;VLE</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="59762-1391" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Doxazosin mesylate</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>doxazosin mesylate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="8"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="86P6PQK0MU" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DOXAZOSIN MESYLATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="NW1291F1W8" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DOXAZOSIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="J2B2A4N98G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE, UNSPECIFIED FORM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="59762-1391-7" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20300101"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA019668" root="2.16.840.1.113883.3.150"/>
                           <code code="C73605" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA authorized generic"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250509"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="12" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText>capsule shaped</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">CN;8;VLE</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_203F89DD-9A5D-4182-A920-09422DF6438F">
               <id root="2af746b1-dcdf-4251-a47c-8119596bed6c"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <effectiveTime value="20240311"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Doxazosin is an alpha<sub>1</sub> adrenergic antagonist indicated for:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Signs and symptoms of Benign Prostatic Hyperplasia (BPH) (<linkHtml href="#ID_1be375cb-f171-4f67-8a86-76816fd26428">1.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Treatment of Hypertension (<linkHtml href="#ID_60c73951-3c7c-427e-9871-076733df2a0e">1.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_1be375cb-f171-4f67-8a86-76816fd26428">
                     <id root="1be375cb-f171-4f67-8a86-76816fd26428"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1	Benign Prostatic Hyperplasia (BPH) </title>
                     <text>
                        <paragraph>Doxazosin tablet is indicated for the treatment of the signs and symptoms of BPH.</paragraph>
                     </text>
                     <effectiveTime value="20240311"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_60c73951-3c7c-427e-9871-076733df2a0e">
                     <id root="60c73951-3c7c-427e-9871-076733df2a0e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2	Hypertension </title>
                     <text>
                        <paragraph>Doxazosin tablet is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug.</paragraph>
                        <paragraph>Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).</paragraph>
                        <paragraph>Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.</paragraph>
                        <paragraph>Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.</paragraph>
                        <paragraph>Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.</paragraph>
                        <paragraph>Doxazosin tablet may be used alone or in combination with other antihypertensives.</paragraph>
                     </text>
                     <effectiveTime value="20240311"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_8B66E4C8-BBF6-401D-AA82-897014C99EF6">
               <id root="723eebae-6c50-4cd9-9571-ed579ec843c1"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20240311"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>For the treatment of BPH: Initiate therapy at 1 mg once daily. Dose may be titrated at 1 to 2-week intervals, up to 8 mg once daily. (<linkHtml href="#ID_ba602577-4950-402f-9ac5-30639f0ba50d">2.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>For the treatment of hypertension: Initiate therapy at 1 mg once daily. Dose may be titrated as needed, up to 16 mg once daily. (<linkHtml href="#ID_6c9ea29f-fc91-4c69-b4ba-1b86de00a3a6">2.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_95dcd5c9-b233-4fef-9bfa-c56e6ab72ea5">
                     <id root="95dcd5c9-b233-4fef-9bfa-c56e6ab72ea5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	Dosing Information </title>
                     <text>
                        <paragraph>Following the initial dose and with each dose increase of Doxazosin, monitor blood pressure for at least 6 hours following administration. If Doxazosin tablet administration is discontinued for several days, therapy should be restarted using the initial dosing regimen.</paragraph>
                     </text>
                     <effectiveTime value="20240311"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_ba602577-4950-402f-9ac5-30639f0ba50d">
                     <id root="ba602577-4950-402f-9ac5-30639f0ba50d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2	Benign Prostatic Hyperplasia </title>
                     <text>
                        <paragraph>The recommended initial dosage of Doxazosin tablet is 1 mg given once daily either in the morning or evening.</paragraph>
                        <paragraph>Depending on the individual patient’s urodynamics and BPH symptomatology, the dose may be titrated at 1 to 2 week intervals to 2 mg, and thereafter to 4 mg and 8 mg once daily. The maximum recommended dose for BPH is 8 mg once daily.</paragraph>
                        <paragraph>Routinely monitor blood pressure in these patients.</paragraph>
                     </text>
                     <effectiveTime value="20240311"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_6c9ea29f-fc91-4c69-b4ba-1b86de00a3a6">
                     <id root="6c9ea29f-fc91-4c69-b4ba-1b86de00a3a6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3	Hypertension </title>
                     <text>
                        <paragraph>The initial dosage of Doxazosin tablet is 1 mg given once daily. Daily dosage may be doubled up 16 mg once daily, as needed, to achieve the desired reduction in blood pressure.</paragraph>
                     </text>
                     <effectiveTime value="20240311"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_21CD4F4A-256E-4DE7-A272-D7CF401464FD">
               <id root="e2f22dae-cad9-46e3-aedf-e61274fa0ca2"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>Tablets: 1 mg (white), 2 mg (white), 4 mg (white) or 8 mg (white).<br/>Each tablet contains doxazosin mesylate equivalent to 1 mg, 2 mg, 4 mg or 8 mg doxazosin (free base).</paragraph>
               </text>
               <effectiveTime value="20240311"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Tablets: 1 mg, 2 mg, 4 mg, 8 mg. (<linkHtml href="#ID_21CD4F4A-256E-4DE7-A272-D7CF401464FD">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_A25D2630-D1B0-4053-AD77-9DF9810290D7">
               <id root="2c07e1c1-a75f-4bac-a9fe-1bedf6a8bbb7"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>The use of Doxazosin tablet is contraindicated in patients with a hypersensitivity to doxazosin, other quinazolines (e.g., prazosin, terazosin), or any of its components.</paragraph>
               </text>
               <effectiveTime value="20240311"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Hypersensitivity to doxazosin, other quinazolines, or any other ingredient in Doxazosin. (<linkHtml href="#ID_A25D2630-D1B0-4053-AD77-9DF9810290D7">4</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_F615FE91-B96E-48CB-94FA-006A76AF04D7">
               <id root="a564d4f9-af5a-4540-99f8-98e791e1c7ec"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20240311"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Postural hypotension with or without syncope may occur. (<linkHtml href="#ID_5d6c0fc2-ad08-402b-bf13-81ac60143555">5.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Risk of Intraoperative Floppy Iris Syndrome during cataract surgery. (<linkHtml href="#ID_8c6fbbf6-480d-491d-b30a-bfbbd52fe571">5.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Screen for the presence of prostate cancer prior to treatment for BPH and at regular intervals afterwards. (<linkHtml href="#ID_7eb3e2e8-424c-4bec-9766-21f0e40790c4">5.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_5d6c0fc2-ad08-402b-bf13-81ac60143555">
                     <id root="5d6c0fc2-ad08-402b-bf13-81ac60143555"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Postural Hypotension </title>
                     <text>
                        <paragraph>Postural hypotension with or without symptoms (e.g., dizziness) may develop within a few hours following administration of Doxazosin. However, infrequently, symptomatic postural hypotension has also been reported later than a few hours after dosing. As with other alpha-blockers, there is a potential for syncope, especially after the initial dose or after an increase in dosage strength. Advise patient how to avoid symptoms resulting from postural hypotension and what measures to take should they develop.</paragraph>
                        <paragraph>Concomitant administration of Doxazosin with a PDE-5 inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension.</paragraph>
                     </text>
                     <effectiveTime value="20240311"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_8c6fbbf6-480d-491d-b30a-bfbbd52fe571">
                     <id root="8c6fbbf6-480d-491d-b30a-bfbbd52fe571"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Cataract Surgery </title>
                     <text>
                        <paragraph>Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract surgery in some patients on or previously treated with alpha1 blockers. This variant of small pupil syndrome is characterized by the combination of a flaccid iris that billows in response to intraoperative irrigation currents, progressive intraoperative miosis despite preoperative dilation with standard mydriatic drugs, and potential prolapse of the iris toward the phacoemulsification incisions. The patient’s surgeon should be prepared for possible modifications to their surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances. There does not appear to be a benefit of stopping alpha1 blocker therapy prior to cataract surgery.</paragraph>
                     </text>
                     <effectiveTime value="20240311"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_7eb3e2e8-424c-4bec-9766-21f0e40790c4">
                     <id root="7eb3e2e8-424c-4bec-9766-21f0e40790c4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Prostate Cancer </title>
                     <text>
                        <paragraph>Carcinoma of the prostate causes many of the symptoms associated with BPH and the two disorders frequently co‑exist. Carcinoma of the prostate should therefore be ruled out prior to commencing therapy with Doxazosin tablet for the treatment of BPH.</paragraph>
                     </text>
                     <effectiveTime value="20240311"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_8a56c922-cd1e-43ab-a594-eaf0e362b07c">
                     <id root="8a56c922-cd1e-43ab-a594-eaf0e362b07c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	Priapism </title>
                     <text>
                        <paragraph>Alpha<sub>1</sub> antagonists, including doxazosin, have been associated with priapism (painful penile erection, sustained for hours and unrelieved by sexual intercourse or masturbation). This condition can lead to permanent impotence if not promptly treated.</paragraph>
                     </text>
                     <effectiveTime value="20240311"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_F9309A5E-7406-4505-A1DE-F2396DE18BD4">
               <id root="52d88e60-0898-4056-9eb5-dc2abc394c57"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <effectiveTime value="20240311"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most commonly reported adverse reactions from clinical trials are fatigue, malaise, hypotension, and dizziness. (<linkHtml href="#ID_3105eb98-e531-4e8c-96f5-18f82e4b9441">6.1</linkHtml>)</paragraph>
                        <paragraph> </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact </content>
                           <content styleCode="bold">Viatris at 1-877-446-3679 (1-877-4-INFO-RX)</content>
                           <content styleCode="bold"> or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_3105eb98-e531-4e8c-96f5-18f82e4b9441">
                     <id root="3105eb98-e531-4e8c-96f5-18f82e4b9441"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1	Clinical Trials Experience </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                     </text>
                     <effectiveTime value="20240311"/>
                     <component>
                        <section ID="ID_70a23f6a-82d8-44a1-96a7-34a690caa8d1">
                           <id root="70a23f6a-82d8-44a1-96a7-34a690caa8d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="italics">Benign Prostatic Hyperplasia (BPH)</content>
                              <content styleCode="italics"/>
                           </title>
                           <text>
                              <paragraph>The incidence of adverse events has been ascertained from worldwide clinical trials in 965 BPH patients. The incidence rates presented below (Table 2) are based on combined data from seven placebo‑controlled trials involving once-daily administration of Doxazosin tablet in doses of 1 to 16 mg in hypertensives and 0.5 to 8 mg in normotensives. Adverse reactions occurring more than 1% more frequently in BPH patients treated with Doxazosin vs. placebo are summarized in Table 1.</paragraph>
                              <table width="100%">
                                 <caption>Table 1.	Adverse Reactions Occurring More than 1% More Frequently in BPH Patients Treated with Doxazosin Versus Placebo</caption>
                                 <col width="36%"/>
                                 <col width="25%"/>
                                 <col width="39%"/>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">BODY SYSTEM</content>
                                          </paragraph>
                                       </td>
                                       <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Doxazosin <br/>N=665</content>
                                          </paragraph>
                                       </td>
                                       <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Placebo<br/>N=300</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">NERVOUS SYSTEM DISORDERS</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Dizziness<footnote ID="_Ref161050503">Includes vertigo</footnote>
                                          </paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>15.6%</paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>9.0%</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Somnolence</paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>3.0%</paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>1.0%</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">CARDIAC DISORDERS</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Hypotension</paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>1.7%</paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>0%</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Dyspnoea</paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>2.6%</paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>0.3%</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">GASTROINTESTINAL DISORDERS</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Dry Mouth</paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>1.4%</paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>0.3%</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Fatigue</paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>8.0%</paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>1.7%</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>Oedema</paragraph>
                                       </td>
                                       <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>2.7%</paragraph>
                                       </td>
                                       <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>0.7%</paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph> </paragraph>
                              <paragraph>Other adverse reactions occurring less than 1% more frequently in BPH patients treated with Doxazosin vs. placebo but plausibly related to Doxazosin include: palpitations.</paragraph>
                           </text>
                           <effectiveTime value="20240311"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_6e76a5f0-6dff-480b-b719-2550c80f3f3b">
                           <id root="6e76a5f0-6dff-480b-b719-2550c80f3f3b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="italics">Hypertension</content>
                              <content styleCode="italics"/>
                           </title>
                           <text>
                              <paragraph>Doxazosin has been administered to approximately 4000 hypertensive patients in clinical trials, of whom 1679 were included in the hypertension clinical development program. In placebo-controlled studies, adverse events occurred in 49% and 40% of patients in the doxazosin and placebo groups, respectively, and led to discontinuation in 2% of patients in each group.</paragraph>
                              <paragraph>Adverse reactions occurring more than 1% more frequently in hypertensive patients treated with Doxazosin vs. placebo are summarized in Table 1. Postural effects and edema appeared to be dose-related. The prevalence rates presented below are based on combined data from placebo-controlled studies involving once-daily administration of doxazosin at doses ranging from 1 to 16 mg.</paragraph>
                              <table width="100%">
                                 <caption>Table 2.	Adverse Reactions Occurring More than 1% More Frequently in Hypertensive Patients Treated with Doxazosin Versus Placebo</caption>
                                 <col width="44%"/>
                                 <col width="29%"/>
                                 <col width="27%"/>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">BODY SYSTEM</content>
                                          </paragraph>
                                       </td>
                                       <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Doxazosin <br/>N=339</content>
                                          </paragraph>
                                       </td>
                                       <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Placebo<br/>N=336</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">NERVOUS SYSTEM DISORDERS</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Dizziness</paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>19%</paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>9%</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Somnolence</paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>5%</paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>1%</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Rhinitis</paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>3%</paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>1%</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">RENAL AND URINARY DISORDERS</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Polyuria</paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>2%</paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>0%</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">REPRODUCTIVE SYSTEM AND BREAST DISORDERS<br/>GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>Fatigue / Malaise</paragraph>
                                       </td>
                                       <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>12%</paragraph>
                                       </td>
                                       <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>6%</paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Other adverse reactions occurring less than 1% more frequently in hypertensive patients treated with Doxazosin vs. placebo but plausibly related to Doxazosin use include vertigo, hypotension, hot flushes, epistaxis and oedema.</paragraph>
                              <paragraph>Doxazosin has been associated with decreases in white blood cell counts.</paragraph>
                           </text>
                           <effectiveTime value="20240311"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_38831cd0-016d-4ba6-8683-73f9a7db90b5">
                           <id root="38831cd0-016d-4ba6-8683-73f9a7db90b5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="italics">Laboratory Changes Observed in Clinical Studies</content>
                              <content styleCode="italics"/>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Leukopenia/Neutropenia</content>
                              </paragraph>
                              <paragraph>Decreases in mean white blood cell (WBC) and mean neutrophil count were observed in controlled clinical trials of hypertensive patients receiving Doxazosin. In cases where follow-up was available, WBC and neutrophil counts returned to normal after discontinuation of Doxazosin. No patients became symptomatic as a result of the low WBC or neutrophil counts.</paragraph>
                           </text>
                           <effectiveTime value="20240311"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_615eff06-3ae1-4f75-9e7a-07eb557c60cb">
                     <id root="615eff06-3ae1-4f75-9e7a-07eb557c60cb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2	Postmarketing Experience </title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of Doxazosin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>In post-marketing experience, the following additional adverse reactions have been reported: <br/>
                           <content styleCode="italics">Blood and Lymphatic System Disorders: </content>leukopenia, thrombocytopenia;<br/>
                           <content styleCode="italics">Immune System Disorders: </content>allergic reaction;<br/>
                           <content styleCode="italics">Nervous System Disorders: </content>hypoesthesia;<br/>
                           <content styleCode="italics">Eye Disorders: </content>Intraoperative Floppy Iris Syndrome <content styleCode="italics">[see <linkHtml href="#ID_8a56c922-cd1e-43ab-a594-eaf0e362b07c">Warnings and Precautions (5.4)</linkHtml>]</content>; <br/>
                           <content styleCode="italics">Cardiac Disorders: </content>bradycardia;<br/>
                           <content styleCode="italics">Respiratory, Thoracic and Mediastinal Disorders: </content>bronchospasm aggravated;<br/>
                           <content styleCode="italics">Gastrointestinal Disorders: </content>vomiting;<br/>
                           <content styleCode="italics">Hepatobiliary Disorders: </content>cholestasis, hepatitis cholestatic;<br/>
                           <content styleCode="italics">Skin and Subcutaneous Tissue Disorders: </content>urticaria;<br/>
                           <content styleCode="italics">Musculoskeletal and Connective Tissue Disorders: </content>muscle cramps, muscle weakness;<br/>
                           <content styleCode="italics">Renal and Urinary Disorders: </content>hematuria, micturition disorder, micturition frequency, nocturia;<br/>
                           <content styleCode="italics">Reproductive System and Breast Disorders: </content>gynecomastia, priapism.</paragraph>
                     </text>
                     <effectiveTime value="20240311"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_455DDA51-238E-4575-96D5-15A5CC446F2E">
               <id root="e2accedc-02be-4029-8444-7e1ffe106f7e"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <effectiveTime value="20240311"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Strong cytochrome P450 (CYP) 3A inhibitors may increase exposure to doxazosin and increased risk of hypotension. (<linkHtml href="#ID_8c5427df-bfd0-4661-a977-cb20eb465143">7.1</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Concomitant administration of Doxazosin with a phosphodiesterase-5 (PDE-5) inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension. (<linkHtml href="#ID_61ab1928-c2d1-4cf4-b862-4ad24d700753">7.2</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_8c5427df-bfd0-4661-a977-cb20eb465143">
                     <id root="8c5427df-bfd0-4661-a977-cb20eb465143"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1	CYP 3A Inhibitors </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">In vitro</content> studies suggest that doxazosin is a substrate of CYP 3A4. Strong CYP3A inhibitors may increase exposure to doxazosin. Monitor blood pressure and for symptoms of hypotension when Doxazosin is used concomitantly with strong CYP3A inhibitors<content styleCode="italics"> [see</content>
                           <content styleCode="italics">
                              <linkHtml href="#ID_51FBA9D4-F9DE-413C-86B0-66BF98831E47">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240311"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_61ab1928-c2d1-4cf4-b862-4ad24d700753">
                     <id root="61ab1928-c2d1-4cf4-b862-4ad24d700753"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2	Phosphodiesterase-5 (PDE-5) Inhibitors </title>
                     <text>
                        <paragraph>Concomitant administration of Doxazosin with a phosphodiesterase-5 (PDE-5) inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension. Monitor blood pressure and for symptoms of hypotension <content styleCode="italics">[see <linkHtml href="#ID_5d6c0fc2-ad08-402b-bf13-81ac60143555">Warnings and Precautions (5.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240311"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_1AB4A38A-3750-4830-8C62-74E4496C1316">
               <id root="de5e47bb-4e71-4110-b2a6-487aac8b3137"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20240311"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Hepatic Impairment: Monitor for hypotension. (<linkHtml href="#ID_d925b42b-7fe2-49fa-b9de-c76870b66ffe">8.6</linkHtml>, <linkHtml href="#ID_51FBA9D4-F9DE-413C-86B0-66BF98831E47">12.3</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_B3A7C301-5571-4345-AFB7-EFD5DEC04E91">
                     <id root="518c4050-276a-45b7-a7d8-1785472f66b9"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <effectiveTime value="20240311"/>
                     <component>
                        <section ID="ID_14b15b0c-ebaf-425e-8d72-f7a1e8f5d361">
                           <id root="14b15b0c-ebaf-425e-8d72-f7a1e8f5d361"/>
                           <code code="69759-9" codeSystem="2.16.840.1.113883.6.1" displayName="RISKS"/>
                           <title>
                              <content styleCode="underline">Risk Summary</content>
                              <content styleCode="underline"/>
                           </title>
                           <text>
                              <paragraph>The limited available data with Doxazosin in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. However, untreated hypertension during pregnancy can result in increased maternal risks <content styleCode="italics">[see <linkHtml href="#ID_9a807de4-0596-436f-a64f-fbbacb70be67">Clinical Considerations</linkHtml>]</content>. In animal reproduction studies, no adverse developmental effects were observed when doxazosin was orally administered to pregnant rabbits and rats during the period of organogenesis at doses of up to 41 and 20 mg/kg, respectively (exposures in rabbits and rats were 10 and 4 times, respectively, the human AUC exposures with a 12 mg/day therapeutic dose). A dosage regimen of 82 mg/kg/day in the rabbit was associated with reduced fetal survival <content styleCode="italics">[see <linkHtml href="#ID_db49758a-bd55-4d8b-9918-236a2cb0783b">Data</linkHtml>].</content>
                              </paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15‑20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20240311"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_9a807de4-0596-436f-a64f-fbbacb70be67">
                           <id root="9a807de4-0596-436f-a64f-fbbacb70be67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Clinical Considerations</content>
                              <content styleCode="underline"/>
                           </title>
                           <effectiveTime value="20240311"/>
                           <component>
                              <section ID="ID_0985e45f-5971-48e8-91a6-d20eccd59d28">
                                 <id root="0985e45f-5971-48e8-91a6-d20eccd59d28"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Disease-Associated Maternal and/or Embryo/Fetal Risk </title>
                                 <text>
                                    <paragraph>Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage). Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death.</paragraph>
                                 </text>
                                 <effectiveTime value="20240311"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_db49758a-bd55-4d8b-9918-236a2cb0783b">
                           <id root="db49758a-bd55-4d8b-9918-236a2cb0783b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Data</content>
                              <content styleCode="underline"/>
                           </title>
                           <effectiveTime value="20240311"/>
                           <component>
                              <section ID="ID_dcd38772-21a3-4976-aa7c-256755b58737">
                                 <id root="dcd38772-21a3-4976-aa7c-256755b58737"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Animal Data </title>
                                 <text>
                                    <paragraph>Radioactivity was found to cross the placenta following oral administration of labelled doxazosin to pregnant rats. Studies in pregnant rabbits and rats at daily oral doses of up to 41 and 20 mg/kg, respectively (plasma drug concentrations of 10 and 4 times, respectively, the human AUC exposures with a 12 mg/day therapeutic dose), have revealed no evidence of adverse developmental effects. A dosage regimen of 82 mg/kg/day in the rabbit was associated with reduced fetal survival. In peri- and postnatal studies in rats, postnatal development at maternal doses of 40 or 50 mg/kg/day of doxazosin (about 8 times human AUC exposure with a 12 mg/day therapeutic dose) was delayed, as evidenced by slower body weight gain and slightly later appearance of anatomical features and reflexes.</paragraph>
                                 </text>
                                 <effectiveTime value="20240311"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_ECB0F6B0-4DB2-4039-97BF-191B1A5DFEC6">
                     <id root="2a27e983-0ddd-462a-9af5-f6911b8551bb"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <effectiveTime value="20240311"/>
                     <component>
                        <section ID="ID_d2307c6a-a953-448c-87a7-c752ce5fa697">
                           <id root="d2307c6a-a953-448c-87a7-c752ce5fa697"/>
                           <code code="69759-9" codeSystem="2.16.840.1.113883.6.1" displayName="RISKS"/>
                           <title>
                              <content styleCode="underline">Risk Summary</content>
                              <content styleCode="underline"/>
                           </title>
                           <text>
                              <paragraph>There is limited information on the presence of Doxazosin in human milk <content styleCode="italics">[see <linkHtml href="#ID_811b02bd-4e6a-47cd-ba42-8b18852b10f6">Data</linkHtml>]. </content>There is no information on the effects of Doxazosin on the breastfeed infant or the effects on milk production.</paragraph>
                           </text>
                           <effectiveTime value="20240311"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_811b02bd-4e6a-47cd-ba42-8b18852b10f6">
                           <id root="811b02bd-4e6a-47cd-ba42-8b18852b10f6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Data</content>
                              <content styleCode="underline"/>
                           </title>
                           <text>
                              <paragraph>A single case study reports that Doxazosin is present in human milk, which resulted in an infant dose of less than 1% of the maternal weight-adjusted dosage and a milk/plasma ratio of 0.1. However, these data are insufficient to confirm the presence of Doxazosin in human milk.</paragraph>
                           </text>
                           <effectiveTime value="20240311"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_1C124D63-1C41-42B6-B528-7325F2420F25">
                     <id root="b488ed0d-a359-46a4-a057-c5377d371f20"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>The safety and effectiveness of Doxazosin have not been established in children.</paragraph>
                     </text>
                     <effectiveTime value="20240311"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_9B257F2E-945A-4F9B-90C5-571BAB833F64">
                     <id root="31653683-b387-4e7b-9693-3805cb2aa58c"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <effectiveTime value="20240311"/>
                     <component>
                        <section ID="ID_c4e23130-6a22-487e-8580-c29e1ef18466">
                           <id root="c4e23130-6a22-487e-8580-c29e1ef18466"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="italics">Benign Prostatic Hyperplasia (BPH)</content>
                              <content styleCode="italics"/>
                           </title>
                           <text>
                              <paragraph>The safety and effectiveness profile of Doxazosin tablet was similar in the elderly (age ≥ 65 years) and younger (age &lt; 65 years) patients.</paragraph>
                           </text>
                           <effectiveTime value="20240311"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_2c94693b-b090-47c9-8a95-3e9e7825bf0b">
                           <id root="2c94693b-b090-47c9-8a95-3e9e7825bf0b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="italics">Hypertension</content>
                              <content styleCode="italics"/>
                           </title>
                           <text>
                              <paragraph>Clinical studies of Doxazosin tablet did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.</paragraph>
                              <paragraph>In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                           </text>
                           <effectiveTime value="20240311"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_d925b42b-7fe2-49fa-b9de-c76870b66ffe">
                     <id root="d925b42b-7fe2-49fa-b9de-c76870b66ffe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6	Hepatic Impairment </title>
                     <text>
                        <paragraph>Doxazosin is extensively metabolized in the liver. Hepatic impairment is expected to increase exposure to doxazosin. Use of Doxazosin in patients with severe hepatic impairment (Child-Pugh Class C) is not recommended. Monitor blood pressure and for symptoms of hypotension in patients with lesser degrees of hepatic impairment (Child-Pugh Class A and B) <content styleCode="italics">[see <linkHtml href="#ID_51FBA9D4-F9DE-413C-86B0-66BF98831E47">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240311"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_C2098001-DBEB-4C9B-9380-CF6ABC2AAEDE">
               <id root="aa523544-a7a0-41b4-b63c-960ad759d289"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE </title>
               <text>
                  <paragraph>Experience with Doxazosin tablet overdosage is limited. Two adolescents, who each intentionally ingested 40 mg Doxazosin tablet with diclofenac or acetaminophen, were treated with gastric lavage with activated charcoal and made full recoveries. A two‑year‑old child who accidently ingested 4 mg Doxazosin tablet was treated with gastric lavage and remained normotensive during the five‑hour emergency room observation period. A six‑month‑old child accidentally received a crushed 1 mg tablet of Doxazosin tablet and was reported to have been drowsy. A 32‑year‑old female with chronic renal failure, epilepsy, and depression intentionally ingested 60 mg Doxazosin tablet (blood level = 0.9 mcg/mL; normal values in hypertensives = 0.02 mcg/mL); death was attributed to a grand mal seizure resulting from hypotension. A 39‑year‑old female who ingested 70 mg Doxazosin tablet, alcohol, and Dalmane<sup>®</sup> (flurazepam) developed hypotension which responded to fluid therapy.</paragraph>
                  <paragraph>The oral LD<sub>50</sub> of doxazosin is greater than 1000 mg/kg in mice and rats. The most likely manifestation of overdosage would be hypotension, for which the usual treatment would be intravenous infusion of fluid. As doxazosin is highly protein bound, dialysis would not be indicated.</paragraph>
               </text>
               <effectiveTime value="20240311"/>
            </section>
         </component>
         <component>
            <section ID="ID_19F9D1CF-1250-4377-9BBA-C1D4D56913A4">
               <id root="f38eeab7-e2be-436b-bf3b-16ea3f417292"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>Doxazosin is a quinazoline compound that is a selective inhibitor of the alpha<sub>1</sub> subtype of alpha-adrenergic receptors. The chemical name of Doxazosin is 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl) piperazine methanesulfonate. The empirical formula for Doxazosin is C<sub>23</sub>H<sub>25</sub>N<sub>5</sub>O<sub>5 </sub>• CH<sub>4</sub>O<sub>3</sub>S and the molecular weight is 547.6. It has the following structure:</paragraph>
                  <renderMultiMedia ID="id-328052997" referencedObject="dd404a16-9f8b-4514-a2c3-edbb039c4478"/>
                  <paragraph>Doxazosin is freely soluble in dimethylsulfoxide, soluble in dimethylformamide, slightly soluble in methanol, ethanol, and water (0.8% at 25°C), and very slightly soluble in acetone and methylene chloride. Doxazosin tablet is available as tablets for oral use and contains doxazosin mesylate equivalent to 1 mg (white), 2 mg (white), 4 mg (white) and 8 mg (white) of doxazosin as the free base.</paragraph>
                  <paragraph>The inactive ingredients for all tablets are lactose, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate and sodium starch glycolate. </paragraph>
               </text>
               <effectiveTime value="20240311"/>
               <component>
                  <observationMedia ID="dd404a16-9f8b-4514-a2c3-edbb039c4478">
                     <text>Doxazosin Structural Formula</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_A54EEDE2-DBAB-45F1-A178-87557C637EFF">
               <id root="24de8834-1a81-4204-9d51-9f6bbd91392a"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20240311"/>
               <component>
                  <section ID="ID_9DFA6950-41E6-4590-A5AE-44747A0F688E">
                     <id root="5cf05c83-9d41-4ba2-891d-ebc1870b9c61"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <effectiveTime value="20240311"/>
                     <component>
                        <section ID="ID_0adca95c-858b-4a0d-9004-4fac0fc3351e">
                           <id root="0adca95c-858b-4a0d-9004-4fac0fc3351e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="italics">Benign Prostatic Hyperplasia (BPH)</content>
                              <content styleCode="italics"/>
                           </title>
                           <text>
                              <paragraph>The symptoms associated with benign prostatic hyperplasia (BPH), such as urinary frequency, nocturia, weak stream, hesitancy, and incomplete emptying are related to two components, anatomical (static) and functional (dynamic). The static component is related to an increase in prostate size caused, in part, by a proliferation of smooth muscle cells in the prostatic stroma. However, the severity of BPH symptoms and the degree of urethral obstruction do not correlate well with the size of the prostate. The dynamic component of BPH is associated with an increase in smooth muscle tone in the prostate and bladder neck. The degree of tone in this area is mediated by the alpha<sub>1</sub> adrenoceptor, which is present in high density in the prostatic stroma, prostatic capsule and bladder neck. Blockade of the alpha<sub>1</sub> receptor decreases urethral resistance and may relieve the obstruction and BPH symptoms and improve urine flow.</paragraph>
                           </text>
                           <effectiveTime value="20240311"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_5ab3f8d3-74a7-48ef-a2e6-3b4396a02f9f">
                           <id root="5ab3f8d3-74a7-48ef-a2e6-3b4396a02f9f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="italics">Hypertension</content>
                              <content styleCode="italics"/>
                           </title>
                           <text>
                              <paragraph>The mechanism of action of Doxazosin tablet is selective blockade of the alpha<sub>1</sub> (postjunctional) subtype of adrenergic receptors. Studies in normal human subjects have shown that doxazosin competitively antagonized the pressor effects of phenylephrine (an alpha<sub>1</sub> agonist) and the systolic pressor effect of norepinephrine. Doxazosin and prazosin have similar abilities to antagonize phenylephrine. The antihypertensive effect of Doxazosin tablet results from a decrease in systemic vascular resistance. The parent compound doxazosin is primarily responsible for the antihypertensive activity. The low plasma concentrations of known active and inactive metabolites of doxazosin (2-piperazinyl, 6'- and 7'-hydroxy and 6- and 7-O-desmethyl compounds) compared to parent drug indicate that the contribution of even the most potent compound (6'-hydroxy) to the antihypertensive effect of doxazosin in man is probably small. The 6'- and 7'-hydroxy metabolites have demonstrated antioxidant properties at concentrations of 5 µM, <content styleCode="italics">in vitro</content>.</paragraph>
                           </text>
                           <effectiveTime value="20240311"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_9B328C46-F2FE-4717-8885-33FBBDDD9FB6">
                     <id root="b42d4dde-dfc4-4737-99d6-472afc480e17"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics </title>
                     <effectiveTime value="20240311"/>
                     <component>
                        <section ID="ID_6f0e2bf7-3506-4501-af1c-a07c1ae86f9c">
                           <id root="6f0e2bf7-3506-4501-af1c-a07c1ae86f9c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="italics">Benign Prostatic Hyperplasia (BPH)</content>
                              <content styleCode="italics"/>
                           </title>
                           <text>
                              <paragraph>Administration of Doxazosin to patients with symptomatic BPH resulted in a statistically significant improvement in maximum urinary flow rate <content styleCode="italics">[see <linkHtml href="#ID_0a87c446-d6d5-4eb9-ad2d-5060b928578e">Clinical Studies (14.1)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20240311"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_5e0763af-ee26-408a-9c41-b3ec14a6edcc">
                           <id root="5e0763af-ee26-408a-9c41-b3ec14a6edcc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="italics">Effect on Normotensive Patients with Benign Prostatic Hyperplasia (BPH)</content>
                              <content styleCode="italics"/>
                           </title>
                           <text>
                              <paragraph>Although blockade of alpha<sub>1</sub> adrenoceptors also lowers blood pressure in hypertensive patients with increased peripheral vascular resistance, Doxazosin tablet treatment of normotensive men with BPH did not result in a clinically significant blood pressure lowering effect (Table 4). The proportion of normotensive patients with a sitting systolic blood pressure less than 90 mmHg and/or diastolic blood pressure less than 60 mmHg at any time during treatment with Doxazosin tablet 1-8 mg once daily was 6.7% with doxazosin and not significantly different (statistically) from that with placebo (5%).</paragraph>
                           </text>
                           <effectiveTime value="20240311"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_3abb9551-2647-4bad-a369-8f0235242ab3">
                           <id root="3abb9551-2647-4bad-a369-8f0235242ab3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="italics">Hypertension</content>
                              <content styleCode="italics"/>
                           </title>
                           <text>
                              <paragraph>Administration of Doxazosin tablet results in a reduction in systemic vascular resistance. In patients with hypertension, there is little change in cardiac output. Maximum reductions in blood pressure usually occur 2-6 hours after dosing and are associated with a small increase in standing heart rate. Like other alpha<sub>1</sub>‑adrenergic blocking agents, doxazosin has a greater effect on blood pressure and heart rate in the standing position.</paragraph>
                           </text>
                           <effectiveTime value="20240311"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_51FBA9D4-F9DE-413C-86B0-66BF98831E47">
                     <id root="5dfd3030-5282-4159-8053-97b771db610e"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <effectiveTime value="20240311"/>
                     <component>
                        <section ID="ID_4b4a0089-314a-4419-904a-42002ebb6612">
                           <id root="4b4a0089-314a-4419-904a-42002ebb6612"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Absorption</content>
                              <content styleCode="underline"/>
                           </title>
                           <text>
                              <paragraph>After oral administration of therapeutic doses, peak plasma levels of Doxazosin tablet occur at about 2-3 hours. Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver. The effect of food on the pharmacokinetics of Doxazosin tablet was examined in a crossover study with twelve hypertensive subjects. Reductions of 18% in mean maximum plasma concentration (C<sub>max</sub>) and 12% in the area under the concentration‑time curve (AUC) occurred when Doxazosin tablet was administered with food. Neither of these differences is clinically significant.</paragraph>
                              <paragraph>In a crossover study in 24 normotensive subjects, the pharmacokinetics and safety of doxazosin were shown to be similar with morning and evening dosing regimens. The AUC after morning dosing was, however, 11% less than that after evening dosing and the time to peak concentration after evening dosing occurred significantly later than that after morning dosing (5.6 vs. 3.5 hours).</paragraph>
                           </text>
                           <effectiveTime value="20240311"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_f12c42f9-a666-4568-9a4c-5317e41013d6">
                           <id root="f12c42f9-a666-4568-9a4c-5317e41013d6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Distribution</content>
                              <content styleCode="underline"/>
                           </title>
                           <text>
                              <paragraph>At the plasma concentrations achieved by therapeutic doses, approximately 98% of the circulating drug is bound to plasma proteins.</paragraph>
                           </text>
                           <effectiveTime value="20240311"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_40ce6887-5faa-4c72-971e-e56d2e95e07b">
                           <id root="40ce6887-5faa-4c72-971e-e56d2e95e07b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Metabolism</content>
                              <content styleCode="underline"/>
                           </title>
                           <text>
                              <paragraph>Doxazosin tablet is extensively metabolized in the liver, mainly by O‑demethylation of the quinazoline nucleus or hydroxylation of the benzodioxan moiety.<content styleCode="italics"> In vitro</content> studies suggest that the primary pathway for elimination is via CYP 3A4; however, CYP 2D6 and CYP 2C9 metabolic pathways are also involved to a lesser extent. Although several active metabolites of doxazosin have been identified, the pharmacokinetics of these metabolites have not been characterized.</paragraph>
                           </text>
                           <effectiveTime value="20240311"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_acc45c16-a6f6-4847-8161-159feb9a5143">
                           <id root="acc45c16-a6f6-4847-8161-159feb9a5143"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Excretion</content>
                              <content styleCode="underline"/>
                           </title>
                           <text>
                              <paragraph>Plasma elimination of doxazosin is biphasic, with a terminal elimination half‑life of about 22 hours. Steady‑state studies in hypertensive patients given doxazosin doses of 2 to 16 mg once daily showed linear kinetics and dose proportionality. In two studies, following the administration of 2 mg orally once daily, the mean accumulation ratios (steady‑state AUC vs. first-dose AUC) were 1.2 and 1.7. Enterohepatic recycling is suggested by secondary peaking of plasma doxazosin concentrations.</paragraph>
                              <paragraph>In a study of two subjects administered radiolabelled doxazosin 2 mg orally and 1 mg intravenously on two separate occasions, approximately 63% of the dose was eliminated in the feces and 9% of the dose was found in the urine. On average only 4.8% of the dose was excreted as unchanged drug in the feces and only a trace of the total radioactivity in the urine was attributed to unchanged drug.</paragraph>
                           </text>
                           <effectiveTime value="20240311"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_356ce8bc-18ea-4d51-a737-30a7d220bcfa">
                           <id root="356ce8bc-18ea-4d51-a737-30a7d220bcfa"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Specific Populations</content>
                              <content styleCode="underline"/>
                           </title>
                           <effectiveTime value="20240311"/>
                           <component>
                              <section ID="ID_2d762011-2f3b-45a1-ae93-abf94e9ad28b">
                                 <id root="2d762011-2f3b-45a1-ae93-abf94e9ad28b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Geriatric </title>
                                 <text>
                                    <paragraph>The pharmacokinetics of Doxazosin tablet in young (&lt;65 years) and elderly (≥65 years) subjects were similar for plasma half‑life values and oral clearance.</paragraph>
                                 </text>
                                 <effectiveTime value="20240311"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_1f9502c0-97c8-442f-9088-c69c1d18b031">
                                 <id root="1f9502c0-97c8-442f-9088-c69c1d18b031"/>
                                 <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                                 <title>Renal Impairment </title>
                                 <text>
                                    <paragraph>Pharmacokinetic studies in elderly patients and patients with renal impairment have shown no significant alterations compared to younger patients with normal renal function.</paragraph>
                                 </text>
                                 <effectiveTime value="20240311"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_40ec7e6a-dd04-4731-977e-6e2e599a170e">
                                 <id root="40ec7e6a-dd04-4731-977e-6e2e599a170e"/>
                                 <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                                 <title>Hepatic Impairment </title>
                                 <text>
                                    <paragraph>Administration of a single 2 mg dose to patients with cirrhosis (Child‑Pugh Class A) showed a 40% increase in exposure to doxazosin. The impact of moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment on the pharmacokinetics of doxazosin is not known <content styleCode="italics">[see <linkHtml href="#ID_d925b42b-7fe2-49fa-b9de-c76870b66ffe">Use in Specific Populations (8.6)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20240311"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_034481e6-ab02-4745-8435-f60edcda1703">
                           <id root="034481e6-ab02-4745-8435-f60edcda1703"/>
                           <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                           <title>
                              <content styleCode="underline">Drug Interactions</content>
                              <content styleCode="underline"/>
                           </title>
                           <text>
                              <paragraph>There are only limited data on the effects of drugs known to influence the hepatic metabolism of doxazosin (e.g., cimetidine).</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Cimetidine: </content>In healthy volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin, and a slight but not significant increase in mean C<sub>max</sub> and mean half-life of doxazosin.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">In vitro </content>data in human plasma indicate that Doxazosin has no effect on protein binding of digoxin, warfarin, phenytoin, or indomethacin.</paragraph>
                           </text>
                           <effectiveTime value="20240311"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_A5A0381F-4258-438B-B7AC-ABB5823DDC2E">
               <id root="e1b96942-01e9-46c2-b4c2-ee39312a16ff"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20240311"/>
               <component>
                  <section ID="ID_60D4A09E-DD89-4734-8C8B-91255E76B8CA">
                     <id root="9d3cfee9-bf87-424a-851b-08af7cf487fe"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <effectiveTime value="20240311"/>
                     <component>
                        <section ID="ID_073eff26-a608-407d-a3ba-dbfaa11a039a">
                           <id root="073eff26-a608-407d-a3ba-dbfaa11a039a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="italics">Carcinogenesis and Mutagenesis</content>
                              <content styleCode="italics"/>
                           </title>
                           <text>
                              <paragraph>Chronic dietary administration (up to 24 months) of Doxazosin at maximally tolerated doses of 40 mg/kg/day in rats and 120 mg/kg/day in mice revealed no evidence of carcinogenic potential. The highest doses evaluated in the rat and mouse studies are associated with AUCs (a measure of systemic exposure) that are 8 times and 4 times, respectively, the human AUC at a dose of 16 mg/day.</paragraph>
                              <paragraph>Mutagenicity studies revealed no drug- or metabolite‑related effects at either chromosomal or subchromosomal levels.</paragraph>
                           </text>
                           <effectiveTime value="20240311"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_15c1b2d7-9490-465e-b8ff-33e3eaf12ba2">
                           <id root="15c1b2d7-9490-465e-b8ff-33e3eaf12ba2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="italics">Fertility in Males</content>
                              <content styleCode="italics"/>
                           </title>
                           <text>
                              <paragraph>Studies in rats showed reduced fertility in males treated with doxazosin at oral doses of 20 (but not 5 or 10) mg/kg/day, about 4 times the AUC exposures obtained with a 12 mg/day human dose. This effect was reversible within two weeks of drug withdrawal. There have been no reports of any effects of doxazosin on male fertility in humans.</paragraph>
                           </text>
                           <effectiveTime value="20240311"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_7962FBB6-F366-439B-B438-0A5418B8DF58">
                     <id root="a5b9c62b-02af-41c5-b0e6-23a29f1395de"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>13.2 Animal Toxicology and Pharmacology </title>
                     <text>
                        <paragraph>An increased incidence of myocardial necrosis or fibrosis was observed in long-term (6-12 months) studies in rats and mice (exposure 8 times human AUC exposure in rats and somewhat equivalent to human C<sub>max</sub> exposure in mice). Findings were not seen at lower doses. In dogs no cardiotoxicity was observed following 12 months of oral dosing at doses that resulted in maximum plasma concentrations (C<sub>max</sub>)<sub/>14 times the C<sub>max </sub>exposure in humans receiving a 12 mg/day therapeutic dose or in Wistar rats at C<sub>max</sub> exposures 15 times human C<sub>max</sub> exposure. There is no evidence that similar lesions occur in humans.</paragraph>
                     </text>
                     <effectiveTime value="20240311"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_72AA6EE9-C723-4CEA-9450-CD05B61F6CDD">
               <id root="4fbbaddb-5003-4676-83d8-5781a03e2226"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES </title>
               <effectiveTime value="20240311"/>
               <component>
                  <section ID="ID_0a87c446-d6d5-4eb9-ad2d-5060b928578e">
                     <id root="0a87c446-d6d5-4eb9-ad2d-5060b928578e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1	Benign Prostatic Hyperplasia (BPH) </title>
                     <text>
                        <paragraph>The efficacy of Doxazosin tablet was evaluated extensively in over 900 patients with BPH in double‑blind, placebo‑controlled trials. Doxazosin tablet treatment was superior to placebo in improving patient symptoms and urinary flow rate. Significant relief with Doxazosin tablet was seen as early as one week into the treatment regimen, with Doxazosin tablet -treated patients (N=173) showing a significant (p&lt;0.01) increase in maximum flow rate of 0.8 mL/sec compared to a decrease of 0.5 mL/sec in the placebo group (N=41). In long‑term studies, improvement was maintained for up to 2 years of treatment. In 66-71% of patients, improvements above baseline were seen in both symptoms and maximum urinary flow rate.</paragraph>
                        <paragraph>In three placebo‑controlled studies of 14-16 weeks’ duration, obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning) of BPH were evaluated at each visit by patient‑assessed symptom questionnaires. The bothersomeness of symptoms was measured with a modified Boyarsky questionnaire. Symptom severity/frequency was assessed using a modified Boyarsky questionnaire or an AUA‑based questionnaire. Uroflowmetric evaluations were performed at times of peak (2-6 hours post‑dose) and/or trough (24 hours post‑dose) plasma concentrations of Doxazosin tablet.</paragraph>
                        <paragraph>The results from the three placebo‑controlled studies (N=609) showing significant efficacy with 4 mg and 8 mg doxazosin are summarized in Table 3. In all three studies, Doxazosin tablet resulted in statistically significant relief of obstructive and irritative symptoms compared to placebo. Statistically significant improvements of 2.3-3.3 mL/sec in maximum flow rate were seen with Doxazosin tablet in Studies 1 and 2, compared to 0.1-0.7 mL/sec with placebo.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 3.</content>
                        </paragraph>
                        <renderMultiMedia ID="id-868614779" referencedObject="ID_7ff7f4a9-fc01-4e0d-88fe-dc405b24eacd"/>
                        <paragraph>In one fixed-dose study (Study 2), Doxazosin tablet therapy (4 to 8 mg, once daily) resulted in a significant and sustained improvement in maximum urinary flow rate of 2.3-3.3 mL/sec (Table 3) compared to placebo (0.1 mL/sec). In this study, the only study in which weekly evaluations were made, significant improvement with Doxazosin tablet vs. placebo was seen after one week. The proportion of patients who responded with a maximum flow rate improvement of ≥3 mL/sec was significantly larger with Doxazosin tablet (34-42%) than placebo (13-17%). A significantly greater improvement was also seen in average flow rate with Doxazosin tablet (1.6 mL/sec) than with placebo (0.2 mL/sec). The onset and time course of symptom relief and increased urinary flow from Study 1 are illustrated in Figure 1.</paragraph>
                        <renderMultiMedia ID="id-1858803759" referencedObject="e064854e-048e-4cfa-9552-5b721d403488">
                           <caption>Figure 1 – Study 1</caption>
                        </renderMultiMedia>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240311"/>
                     <component>
                        <observationMedia ID="ID_7ff7f4a9-fc01-4e0d-88fe-dc405b24eacd">
                           <text>Table 3.</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="image-02.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="e064854e-048e-4cfa-9552-5b721d403488">
                           <text>Figure 1 – Study 1</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="image-03.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_0b38c5c7-b02f-4bed-82ea-f32f9a644eb0">
                     <id root="0b38c5c7-b02f-4bed-82ea-f32f9a644eb0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2	Hypertension </title>
                     <text>
                        <paragraph>In a pooled analysis of placebo-controlled hypertension studies with about 300 hypertensive patients per treatment group, doxazosin, at doses of 1 to 16 mg given once daily, lowered blood pressure at 24 hours by about 10/8 mmHg compared to placebo in the standing position and about 9/5 mmHg in the supine position. Peak blood pressure effects (1-6 hours) were larger by about 50-75% (i.e., trough values were about 55-70% of peak effect), with the larger peak-trough differences seen in systolic pressures. There was no apparent difference in the blood pressure response of Caucasians and blacks or of patients above and below age 65. In the same patient population, patients receiving Doxazosin gained a mean of 0.6 kg compared to a mean loss of 0.1 kg for placebo patients.</paragraph>
                        <table width="100%">
                           <caption>Table 4.	Mean Changes in Blood Pressure from Baseline to the Mean of the Final Efficacy Phase in Normotensives (Diastolic BP &lt;90 mmHg) in Two Double-blind, Placebo-controlled U.S. Studies with Doxazosin 1 to 8 mg Once Daily</caption>
                           <col width="22%"/>
                           <col width="17%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Toprule " valign="top"/>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="underline">PLACEBO</content> (N=85)</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="underline">Doxazosin</content> (N=183)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="underline">Sittin</content>g <content styleCode="underline">BP (mmH</content>g)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="underline">Baseline</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="underline">Chan</content>g<content styleCode="underline">e</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="underline">Baseline</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="underline">Chan</content>g<content styleCode="underline">e</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Systolic</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>128.4</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>-1.4</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>128.8</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>-4.9<footnote ID="_Ref161635171">p ≤0.05 compared to placebo</footnote>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Diastolic</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>79.2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>-1.2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>79.6</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>-2.4<footnoteRef IDREF="_Ref161635171"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="underline">Standin</content>g <content styleCode="underline">BP (mmH</content>g)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="underline">Baseline</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="underline">Chan</content>g<content styleCode="underline">e</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="underline">Baseline</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="underline">Chan</content>g<content styleCode="underline">e</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Systolic</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>128.5</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>-0.6</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>128.5</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>-5.3<footnoteRef IDREF="_Ref161635171"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Diastolic</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>80.5</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>-0.7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>80.4</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>-2.6<footnoteRef IDREF="_Ref161635171"/>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph> </paragraph>
                     </text>
                     <effectiveTime value="20240311"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_2F9B31FF-D770-4B8E-9BA0-4011679AD17D">
               <id root="50bf6c5f-6a00-4df5-9f6e-2510ab10aad4"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>Doxazosin is available as tablets for oral administration. Each tablet contains Doxazosin mesylate equivalent to 1 mg (white), 2 mg (white), 4 mg (white) or 8 mg (white) of doxazosin as the free base.</paragraph>
                  <table width="100%">
                     <col width="40%"/>
                     <col width="13%"/>
                     <col width="47%"/>
                     <tbody>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>NDC and Pack Size</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>Strength</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>Description</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>NDC 59762-1388-7 (Bottle of 100)</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>1 mg</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>White, round tablets with “CN1” on one side and “VLE” on the other side.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>NDC 59762-1389-7 (Bottle of 100)</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>2 mg</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>White, oblong tablets with score and “CN 2” on one side and “VLE” on the other side.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>NDC 59762-1390-7 (Bottle of 100)</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>4 mg</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>White, rhombus shaped tablets with break score and “CN 4” on one side and VLE on the other side.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>NDC 59762-1391-7 (Bottle of 100)</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>8 mg</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>White, capsule shaped tablets with break score and “CN 8” on one side and “VLE” on the other side.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Recommended Storage: Store at 25°C (77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].</paragraph>
               </text>
               <effectiveTime value="20240311"/>
            </section>
         </component>
         <component>
            <section ID="ID_EAC31BD7-7952-4DBF-92A5-5E08AF553CDE">
               <id root="f2de6d74-11b5-4728-89f5-06958992b8c0"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
                  <paragraph>
                     <content styleCode="italics">Postural Hypotension</content>
                  </paragraph>
                  <paragraph>Advise patients of the possibility of syncopal and orthostatic symptoms, especially at the initiation of therapy, and urged to avoid driving or hazardous tasks for 24 hours after the first dose, after a dosage increase, and after interruption of therapy when treatment is resumed. Advise patients to report symptoms to their healthcare provider.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Priapism</content>
                  </paragraph>
                  <paragraph>Advise patients of the possibility of priapism and to seek immediate medical attention if symptoms occur.</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>GREENSTONE<sup>®</sup> BRAND<br/>Distributed by:<br/>
                     <content styleCode="bold">Greenstone LLC</content>
                     <br/>Morgantown, WV 26505 U.S.A.</paragraph>
                  <paragraph>© 2024 Viatris Inc.</paragraph>
                  <paragraph>GST:DOXA:R1</paragraph>
               </text>
               <effectiveTime value="20240311"/>
            </section>
         </component>
         <component>
            <section ID="ID_5fc82fac-45da-4ba5-8560-dd315d7b8688">
               <id root="5fc82fac-45da-4ba5-8560-dd315d7b8688"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title>PATIENT INFORMATION  </title>
               <text>
                  <table cellpadding="0pt" width="100%">
                     <col width="23%"/>
                     <col width="24%"/>
                     <col width="51%"/>
                     <col width="2%"/>
                     <tbody>
                        <tr>
                           <td colspan="4" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Doxazosin</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(Doxazosin tablets)</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What is Doxazosin?</content>
                              </paragraph>
                              <paragraph>Doxazosin is a prescription medicine that contains Doxazosin and is called an “alpha-blocker”. Doxazosin is used to treat:</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>the symptoms of benign prostatic hyperplasia (BPH)</item>
                                 <item>
                                    <caption>•</caption>high blood pressure (hypertension)</item>
                              </list>
                              <paragraph>It is not known if Doxazosin is safe and effective in children.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Who should not take Doxazosin? Do not take </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Doxazosin if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>are allergic to doxazosin, other quinazolines, or any of the ingredients in Doxazosin. See the end of this Patient Information leaflet for a complete list of ingredients in Doxazosin.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What should I tell my healthcare provider before taking Doxazosin?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Before taking Doxazosin, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>have had low blood pressure, especially after taking other medicine. Signs of low blood pressure include fainting, dizziness, and lightheadedness.</item>
                                 <item>
                                    <caption>•</caption>have any planned eye surgery</item>
                                 <item>
                                    <caption>•</caption>have prostate cancer or a history of prostate cancer. Your healthcare provider may have you checked for prostate cancer before you start taking and while you take Doxazosin.</item>
                                 <item>
                                    <caption>•</caption>have liver problems</item>
                                 <item>
                                    <caption>•</caption>are pregnant or plan to become pregnant. It is not known if Doxazosin will harm your unborn baby.</item>
                                 <item>
                                    <caption>•</caption>are breastfeeding or plan to breastfeed. It is not known if Doxazosin passes into your breastmilk. Talk to your healthcare provider about the best way to feed your baby if you take Doxazosin.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements. Doxazosin may affect the way other medicines work, and other medicines may affect the way Doxazosin works causing side effects.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Especially tell your healthcare provider if you take:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>other medicine for high blood pressure or medicine to treat erectile dysfunction (ED) called a phosphodiesterase type 5 (PDE-5) inhibitor. The use of Doxazosin with PDE-5 inhibitors can lead to a drop in blood pressure or to fainting.</item>
                              </list>
                              <paragraph>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">How should I take Doxazosin?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Take Doxazosin exactly as your healthcare provider tells you to take it.</item>
                                 <item>
                                    <caption>•</caption>Your healthcare provider will tell you how much Doxazosin to take and when to take it.</item>
                                 <item>
                                    <caption>•</caption>Your healthcare provider may need to change your dose of Doxazosin until it is the right dose for you.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What should I avoid while taking Doxazosin?</content>
                              </paragraph>
                              <paragraph>Do not drive or perform any hazardous task until at least 24 hours after you have taken Doxazosin if you are taking:</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>your first dose of Doxazosin</item>
                                 <item>
                                    <caption>•</caption>Doxazosin for the first time <content styleCode="bold">after</content> your healthcare provider has increased your dose of Doxazosin</item>
                                 <item>
                                    <caption>•</caption>Doxazosin for the first time <content styleCode="bold">after</content> any breaks (interruptions) in your treatment with Doxazosin</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of Doxazosin? Doxazosin may cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">A sudden drop in blood pressure,</content> especially when you first start treatment or when there is an increase in your dose of Doxazosin, is common but can also be serious. This may cause you to faint, or to feel dizzy or lightheaded. Your risk of having this problem may be increased if you take Doxazosin with certain other medicines that lower blood pressure including PDE-5 inhibitors. Your healthcare provider may monitor your blood pressure while you take Doxazosin. See “What should I avoid while taking Doxazosin?”.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Eye problems during cataract surgery</content>. A condition called Intraoperative Floppy Iris Syndrome (IFIS) can happen during cataract surgery if you take or have taken alpha-blockers such as Doxazosin. If you need to have cataract surgery, be sure to tell your healthcare provider if you take or have taken Doxazosin.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">A painful erection that will not go away</content>. Doxazosin can cause a painful erection (priapism), which cannot be relieved by having sex. If this happens, get medical help right away. If priapism is not treated, you may not be able to get an erection in the future.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">The most common side effects of Doxazosin are:</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>weakness or lack of energy (asthenia)</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>dizziness</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Doxazosin. For more information, ask your healthcare provider or pharmacist.</paragraph>
                              <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of Doxazosin.</content>
                              </paragraph>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Doxazosin for a condition for which it was not prescribed. Do not give Doxazosin to other people, even if they have the same symptoms you have. It may harm them.</paragraph>
                              <paragraph>This Patient Information leaflet summarizes the most important information about Doxazosin. For more information, ask your healthcare provider. You can ask your healthcare provider or pharmacist for information that is written for healthcare professionals.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in Doxazosin?</content>
                              </paragraph>
                              <paragraph>The size, shape and appearance of the tablet that you receive may vary, all the tablets have the same active ingredient, and this will not affect the way that the medicine works. You can identify the tablet that you have from the following information.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph> Strength</paragraph>
                           </td>
                           <td colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                           <td styleCode="Rrule Lrule " valign="top"/>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph> 1 mg Tablet</paragraph>
                           </td>
                           <td colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph> White, round tablets with “CN1” on one side and “VLE” on the other side.</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule " valign="top"/>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph> 2 mg Tablet</paragraph>
                           </td>
                           <td colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph> White, oblong tablets with score and “CN 2” on one side and “VLE” on the other side.</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule " valign="top"/>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph> 4 mg Tablet</paragraph>
                           </td>
                           <td colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph> White, rhombus shaped tablets with break score and “CN 4” on one side and “VLE” on the other side.</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule " valign="top"/>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph> 8 mg Tablet</paragraph>
                           </td>
                           <td colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph> White, capsule shaped tablets with break score and “CN 8” on one side and “VLE” on the other side.</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule " valign="top"/>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Active ingredient:</content> Doxazosin</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Inactive ingredients:</content> lactose, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate and sodium starch glycolate.</paragraph>
                              <paragraph> </paragraph>
                              <paragraph>GREENSTONE<sup>®</sup> BRAND<br/>Distributed by:<br/>
                                 <content styleCode="bold">Greenstone LLC</content>
                                 <br/>Morgantown, WV 26505 U.S.A.</paragraph>
                              <paragraph> </paragraph>
                              <paragraph>© 2024 Viatris Inc.</paragraph>
                              <paragraph> </paragraph>
                              <paragraph>GST:PL:DOXA:R1</paragraph>
                              <paragraph> </paragraph>
                              <paragraph>For more information, call 1-877-446-3679 (1-877-4-INFO-RX).</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration.       Revised: 3/2024</paragraph>
               </text>
               <effectiveTime value="20240311"/>
            </section>
         </component>
         <component>
            <section ID="ID_C0ADE8C6-6AC0-4CD4-BD38-55B358BBBD34">
               <id root="776de165-64ba-4de3-94ad-0f377d4061c3"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL – 1 mg </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 59762-1388-7</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 Tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">doxazosin<br/>tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1 mg*</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Store at 25°C (77°F);<br/>excursions permitted<br/>from 15°C to 30°C<br/>(59°F to 86°F)</content>
                     <br/>[see USP Controlled<br/>Room Temperature].</paragraph>
                  <paragraph>
                     <content styleCode="bold">Recommended Dosage</content>
                     <br/>See prescribing information.<br/>*Each tablet contains<br/>doxazosin mesylate<br/>equivalent to 1 mg<br/>doxazosin as a free base.</paragraph>
                  <paragraph>Made in Germany</paragraph>
                  <paragraph>Distributed by:<br/>
                     <content styleCode="bold">Greenstone LLC</content>
                     <br/>Morgantown, WV 26505 U.S.A.</paragraph>
                  <paragraph>© 2024 Viatris Inc.</paragraph>
                  <paragraph>RGST1388A</paragraph>
                  <renderMultiMedia ID="id270134187" referencedObject="ID_343b4ae2-6db5-4b75-803e-f6574109a965"/>
               </text>
               <effectiveTime value="20240311"/>
               <component>
                  <observationMedia ID="ID_343b4ae2-6db5-4b75-803e-f6574109a965">
                     <text>Doxazosin Tablets Bottle Labels 1 mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_E1D65D78-305F-4180-BDC4-8DAD1D304380">
               <id root="b54bede9-bb9e-40dd-871c-d3c3dccd40f1"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL – 2 mg  </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 59762-1389-7</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 Tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">doxazosin<br/>tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">2 mg*</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Store at 25°C (77°F);<br/>excursions permitted<br/>from 15°C to 30°C<br/>(59°F to 86°F)</content>
                     <br/>[see USP Controlled<br/>Room Temperature].</paragraph>
                  <paragraph>
                     <content styleCode="bold">Recommended Dosage</content>
                     <br/>See prescribing information.<br/>*Each tablet contains<br/>doxazosin mesylate<br/>equivalent to 2 mg<br/>doxazosin as a free base.</paragraph>
                  <paragraph>Made in Germany</paragraph>
                  <paragraph>Distributed by:<br/>
                     <content styleCode="bold">Greenstone LLC</content>
                     <br/>Morgantown, WV 26505 U.S.A.</paragraph>
                  <paragraph>© 2024 Viatris Inc.</paragraph>
                  <paragraph>RGST1389A</paragraph>
                  <renderMultiMedia ID="id-1511362083" referencedObject="ID_9f18385a-c475-4443-9277-ddc6eb6bab15"/>
               </text>
               <effectiveTime value="20240311"/>
               <component>
                  <observationMedia ID="ID_9f18385a-c475-4443-9277-ddc6eb6bab15">
                     <text>Doxazosin Tablets Bottle Labels 2 mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_53552AD3-CDF2-4C75-B96E-48DAAA589165">
               <id root="68538c7f-557f-4747-84f5-285637debe5a"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL – 4 mg </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 59762-1390-7</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 Tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">doxazosin<br/>tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">4 mg*</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Store at 25°C (77°F);<br/>excursions permitted<br/>from 15°C to 30°C<br/>(59°F to 86°F)</content>
                     <br/>[see USP Controlled<br/>Room Temperature].</paragraph>
                  <paragraph>
                     <content styleCode="bold">Recommended Dosage</content>
                     <br/>See prescribing information.<br/>*Each tablet contains<br/>doxazosin mesylate<br/>equivalent to 4 mg<br/>doxazosin as a free base.</paragraph>
                  <paragraph>Made in Germany</paragraph>
                  <paragraph>Distributed by:<br/>
                     <content styleCode="bold">Greenstone LLC</content>
                     <br/>Morgantown, WV 26505 U.S.A.</paragraph>
                  <paragraph>© 2024 Viatris Inc.</paragraph>
                  <paragraph>RGST1390A</paragraph>
                  <renderMultiMedia ID="id363267714" referencedObject="f9e139b2-f90b-4c95-93fe-43dcd95d8981"/>
               </text>
               <effectiveTime value="20240311"/>
               <component>
                  <observationMedia ID="f9e139b2-f90b-4c95-93fe-43dcd95d8981">
                     <text>Doxazosin Tablets Bottle Labels 4 mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_A17152DB-E451-4098-A0F8-8990FDE0E814">
               <id root="cda2ac00-21ab-474a-89d9-d4ccac1f54aa"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL – 8 mg </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 59762-1391-7</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 Tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">doxazosin<br/>tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">8 mg*</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Store at 25°C (77°F);<br/>excursions permitted<br/>from 15°C to 30°C<br/>(59°F to 86°F)</content>
                     <br/>[see USP Controlled<br/>Room Temperature].</paragraph>
                  <paragraph>
                     <content styleCode="bold">Recommended Dosage</content>
                     <br/>See prescribing information.<br/>*Each tablet contains<br/>doxazosin mesylate<br/>equivalent to 8 mg<br/>doxazosin as a free base.</paragraph>
                  <paragraph>Made in Germany</paragraph>
                  <paragraph>Distributed by:<br/>
                     <content styleCode="bold">Greenstone LLC</content>
                     <br/>Morgantown, WV 26505 U.S.A.</paragraph>
                  <paragraph>© 2024 Viatris Inc.</paragraph>
                  <paragraph>RGST1391A</paragraph>
                  <renderMultiMedia ID="id520671240" referencedObject="ID_35b029cf-d244-4d1c-bbbf-db605cb0f599"/>
               </text>
               <effectiveTime value="20240311"/>
               <component>
                  <observationMedia ID="ID_35b029cf-d244-4d1c-bbbf-db605cb0f599">
                     <text>Doxazosin Tablets Bottle Labels 8 mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>